Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) EBIT Margin (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of EBIT Margin readings, the most recent being 4.12% for Q1 2026.

  • On a quarterly basis, EBIT Margin fell 39.0% to 4.12% in Q1 2026 year-over-year; TTM through Jan 2026 was 7.25%, a 255.0% increase, with the full-year FY2025 number at 7.08%, up 646.0% from a year prior.
  • EBIT Margin hit 4.12% in Q1 2026 for Pharma-Bio Serv, up from 6.2% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 10.06% in Q3 2023 to a low of 18.41% in Q1 2024.
  • Median EBIT Margin over the past 5 years was 3.73% (2025), compared with a mean of 2.31%.
  • Biggest five-year swings in EBIT Margin: skyrocketed 8936bps in 2022 and later crashed -2617bps in 2024.
  • Pharma-Bio Serv's EBIT Margin stood at 3.64% in 2022, then crashed by -139bps to 1.44% in 2023, then plummeted by -359bps to 6.61% in 2024, then grew by 6bps to 6.2% in 2025, then skyrocketed by 34bps to 4.12% in 2026.
  • The last three reported values for EBIT Margin were 4.12% (Q1 2026), 6.2% (Q4 2025), and 15.99% (Q3 2025) per Business Quant data.